Open AccessSacubitril/valsartan in heart failure and end‐stage renal insufficiency
Author(s) -
Heyse Alex,
Manhaeghe Lynn,
Mahieu Elien,
Vanfraechem Céline,
Van Durme Frederik
Publication year - 2019
Publication title -
esc heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.787
H-Index - 25
ISSN - 2055-5822
DOI - 10.1002/ehf2.12544
Subject(s) - sacubitril , medicine , sacubitril, valsartan , valsartan , heart failure , hemodialysis , cardiology , ejection fraction , tolerability , blood pressure , intensive care medicine , adverse effect
The aim of this report is to describe the feasibility and tolerability of medical treatment with sacubitril/valsartan in a patient treated with hemodialysis. We describe the case of a 67‐year‐old man with heart failure with reduced ejection fraction due to an ischemic cardiomyopathy and renal insufficiency undergoing hemodialysis. Because of worsening heart failure with no other therapeutic options, a treatment with sacubitril/valsartan was started. Although this patient had a very low systolic blood pressure, he could tolerate a moderate dose of 49/51 mg twice daily. After initiation of sacubitril/valsartan, there was a symptomatic improvement with a clear reduction NT‐proBNP, accompanied by a decrease in filling pressures. In conclusion, in this patient with severe heart failure undergoing hemodialysis, treatment with sacubitril/valsartan was feasible, safe, and improved heart failure symptoms.